Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Samsara Inc (IOT) vs Novo Nordisk A/S (NVO) Price & Performance

Samsara IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Samsara Inc vs Novo Nordisk A/S — how do they compare? Samsara Inc trades at $39.79 (market cap $23.23B), while Novo Nordisk A/S trades at $45.81 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 8.9× Samsara Inc's market cap, and Novo Nordisk A/S pays a 3.76% dividend while Samsara Inc pays none. Which is the better fit depends on your goals.

IOTNVO
Market Cap
$23.23B$207.31B
Sector
TechnologyHealth
52-Week High
$45.22$63.98
52-Week Low
$24.25$35.29
Enterprise Value
$22.49B$222.02B
Dividend Yield
3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Samsara Inc

Samsara (IOT) trades at $40.88, up 6.96% in the last session, with a bullish technical signal from moving averages. The company reported revenue of $1.25B in 2025 but a net loss of $154.91M, though it has beaten EPS estimates for three consecutive quarters. Analyst sentiment is strongly positive, with 14 of 18 analysts rating it a Buy and a consensus price target of $44.50. Recent news highlights institutional buying and the company's focus on AI-driven growth.

The outlook is optimistic due to strong analyst support and consistent earnings beats, but risks include high valuation multiples and ongoing profitability challenges. Investors should weigh the growth potential in AI and connected operations against the current negative net income and elevated P/E ratio of 398.6.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.

Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Samsara Inc

Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.

Read more on IOT

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO